Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Cristina Migali"'
Autor:
Angela George, Jennifer McLachlan, Nina Tunariu, Chiara Della Pepa, Cristina Migali, Martin Gore, Stan Kaye, Susana Banerjee
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-8 (2017)
Abstract Background Hormonal therapy is used as a treatment option in high-grade ovarian carcinoma (HGOC), but the role and choice of treatment remains unclear. Agents used include tamoxifen and aromatase inhibitors. Our aim was to evaluate the effic
Externí odkaz:
https://doaj.org/article/1e15640a836d4f53abc6ee7cfc718d0e
Autor:
Cristina Migali, Monica Milano, Dario Trapani, Carmen Criscitiello, Angela Esposito, Marzia Locatelli, Ida Minchella, Giuseppe Curigliano
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 8 (2016)
Is breast cancer (BC) immunogenic? Many data suggest that it is. Many observations demonstrated the prognostic role of tumor-infiltrating lymphocytes (TILs) in triple negative (TN) and human epidermal growth factor receptor 2 (HER-2)-positive BC. TNB
Externí odkaz:
https://doaj.org/article/b63950ae488c4cb184d3e41f210b3f07
Autor:
Cinzia Solinas, Cristina Migali, Karen Willard-Gallo, Marco Aiello, Antonino Musolino, Zuzana Hlavata, Benedetta Pellegrino, Pushpamali De Silva
Publikováno v:
Molecular Diagnosis & Therapy
Hormone-receptor positive (HR+) breast cancer (BC) (including the luminal A and the luminal B subtypes) is the most common type of tumor in women diagnosed with early-stage BC (EBC). It represents a highly heterogeneous subgroup that is characterized
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c3afe799d4a823a935a7b9924358880
https://doi.org/10.1007/s40291-021-00525-7
https://doi.org/10.1007/s40291-021-00525-7
Autor:
Luca Saba, Alfredo Addeo, Michele Porcu, Karen Willard-Gallo, Cinzia Solinas, M. Schena, Angelo F. Battaglia, Cristina Migali, Lorenzo Di Cesare Mannelli
Publikováno v:
Targeted oncology. 15(1)
The immunotherapy revolution in cancer treatment involves a variety of specialists, not only oncologists, but also internal medicine physicians, endocrinologists, dermatologists, gastroenterologists, rheumatologists, and radiologists, introducing new
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::765116705f95d5f1f948d09af83813a5
https://pubmed.ncbi.nlm.nih.gov/31925647
https://pubmed.ncbi.nlm.nih.gov/31925647
Autor:
Jennifer McLachlan, Stan B. Kaye, Susana Banerjee, Nina Tunariu, Cristina Migali, Angela George, Martin Gore, Chiara Della Pepa
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-8 (2017)
BMC Cancer
BMC Cancer
Background Hormonal therapy is used as a treatment option in high-grade ovarian carcinoma (HGOC), but the role and choice of treatment remains unclear. Agents used include tamoxifen and aromatase inhibitors. Our aim was to evaluate the efficacy of ta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64602aefdf462fcb47394e9ca1da905b
http://link.springer.com/article/10.1186/s12885-017-3440-0
http://link.springer.com/article/10.1186/s12885-017-3440-0
Publikováno v:
Lung Cancer Management. 3:417-428
SUMMARY The diagnostic pathway of lung cancer is a multidisciplinary process that has rapidly changed in the last few years. Most advances relate to lung adenocarcinoma, which needs to be differentiated from squamous cell carcinoma and other histolog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::996c2ce19fabc0ef03e92ea8243a6e17
https://doi.org/10.2217/lmt.14.34
https://doi.org/10.2217/lmt.14.34
Autor:
Lucia Loiacono, Gabriella Misso, A. Carducci, Felice Arcuri, Cinzia Remondo, Cristina Migali, Pierfrancesco Tassone, Monica Marra, Michele Caraglia, Maria Teresa Del Vecchio, Pierosandro Tagliaferri, Pierpaolo Correale, Alberto Abbruzzese
Publikováno v:
European Journal of Cancer. 46:1703-1711
Cetuximab is a human-murine chimeric IgG1 monoclonal antibody to epidermal growth factor-receptor (EGFR) which exerts synergistic antitumour interactions with several cytotoxic drugs. Therefore, it is presently recommended in combination with chemoth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0dd4554dec1eb5f7e48163b906fcc5a
https://doi.org/10.1016/j.ejca.2010.03.005
https://doi.org/10.1016/j.ejca.2010.03.005
Autor:
Antonella Licchetta, Raffaele Addeo, Cinzia Remondo, Cristina Migali, Salvatore Francesco Carbone, Guido Francini, Giuseppe Gotti, Veronica Ricci, Pierpaolo Correale, Pierfrancesco Tassone, Maria Saveria Rotundo, Pierosandro Tagliaferri, Alberto Abbruzzese, Luca Volterrani, Pasquale Sperlongano, Michele Caraglia, Ignazio Martellucci
Publikováno v:
Cancer Biology & Therapy. 9:685-693
Background: We designed a translational clinical trial to investigate whether a dose/dense chemotherapy regimen is able to enhance in patients with non-small-cell-lung-cancer, the anti-angiogenic, and anti-tumor activity of bevacizumab, a murine/huma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::639352262ffa4c9f016cd84e6edece99
https://doi.org/10.4161/cbt.9.9.11441
https://doi.org/10.4161/cbt.9.9.11441
Autor:
Johann S. de Bono, Chiara Della-Pepa, Shelize Khakoo, Susana Banerjee, Steve Hazell, Stanley B. Kaye, Cristina Migali, Nina Tunariu, Saoirse Dolly
Publikováno v:
ESMO Open
Peritoneal mesothelioma (MPeM) is a scarce abdominal-pelvic malignancy that presents with non-specific features and exhibits a wide clinical spectrum from indolent to aggressive disease. Due to it being a rare entity, there is a lack of understanding
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f42284b37fe3168995b9325484abdc45
https://doi.org/10.1136/esmoopen-2016-000101
https://doi.org/10.1136/esmoopen-2016-000101
Autor:
Pierpaolo, Correale, Cinzia, Remondo, Salvatore Francesco, Carbone, Veronica, Ricci, Cristina, Migali, Ignazio, Martellucci, Antonella, Licchetta, Raffaele, Addeo, Luca, Volterrani, Giuseppe, Gotti, Maria Saveria, Rotundo, Pierfrancesco, Tassone, Pasquale, Sperlongano, Alberto, Abbruzzese, Michele, Caraglia, Pierosandro, Tagliaferri, Guido, Francini
Publikováno v:
Cancer biologytherapy. 9(9)
We designed a translational clinical trial to investigate whether a dose/dense chemotherapy regimen is able to enhance in patients with non-small-cell-lung-cancer (NSCLC) the anti-angiogenic effects of bevacizumab, a murine/human monoclonal antibody
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::674af4b187033e0e538f53faa8d79245
https://pubmed.ncbi.nlm.nih.gov/20339315
https://pubmed.ncbi.nlm.nih.gov/20339315